end impress beat head strong momentum
end market healthi fx tailwind contempl compani
signific capac believ well posit gener upsid
guidance/our forecast valuat rel peer remain
attract price target
revenu y/i report y/i organ crush consensu
forecast organ revenu growth also easili beat consensu
expect clearli extrem strong close even
account benefit season product year-end spend encouragingli
busi segment contribut revenu beat segment lp led beat
absolut dollar follow ai lss sdx end market grew msd better
quarter pharma/biotech led growth follow acc/gov hc/dx
hsd industrial/appli msd addit detail page
gross margin declin y/i consensu
forecast declin primarili driven unfavor mix dilut
 despit gross margin come weaker oper margin
light expect due oper leverage/cost save addit
oper margin neg affect relat one-tim bonu payment
exclud payment contempl consensu prior guidanc oper margin
expect
revenu guid organ fx
oper margin expans guid y/i includ pthn dilut
ep guid fx previou forecast
target least good expect use recent rate note fx would
revenu tailwind embed manag guidanc
 equat ep upsid flow revenu ep estim
midpoint guidanc reflect fx tailwind though
still conserv
look well posit end market healthi room
upsid fx core addit still trade percentag point histor
norm rel peer accordingli room multipl expans
arguabl deserv higher multipl given growth profil rais price
target base dcf analysi ep discount peer
premium note upsid ep estim
pleas see page report import disclosur
look well posit end market healthi room
upsid fx core addit late januari trade percentag
point histor norm rel peer accordingli room
multipl expans arguabl deserv higher multipl price target
base dcf analysi ep note upsid ep
ep upsid year
ep upsid year
ep upsid year
thermo fisher engag serv scienc provid analyt instrument equip
reagent consum softwar servic research manufactur analysi
discoveri diagnost oper four segment life scienc solut lss
analyt instrument ai specialti diagnost sdx laboratori product
servic lp lss segment larg consist acquir busi
 deliv rang product servic use across life scienc
appli market diagnost
compani report thomson eikon cowen compani
cowen vs consensu mm except pthn fx organicgross y/i excl pthn patheon fx core select revenu metric mm except scienc product statement mm except currenc item line forecast pre-tax per count rate forecast ep y/i beat consensu forecast beat primarili driven revenu upsid note one-tim bonu payment equat impact ep line forecast streetaccount consensu lss revenu beat consensu forecast organ revenu growth beat forecast growth robust across segment particular strength bioproduct bioscienc busi streetaccount consensu ai revenu beat consensu forecast organ revenu growth beat forecast growth solid across busi streetaccount consensu sdx revenu beat consensu forecast organ revenu growth beat forecast growth strong season product perform clinic transplant diagnost busi phadia one lambda streetaccount consensu lp revenu beat consensu forecast organ revenu growth beat forecast channel busi strong organ revenu growth note busi segment grew well includ clinic trial logist streetaccount consensu organ growth revenu y/i report y/i organ crush consensu forecast organ revenu growth also easili beat expect strong close encouragingli busi segment contribut revenu beat segment lp led beat absolut dollar follow ai lss sdx end market grew msd better quarter pharma/biotech led growth follow acc/gov hc/dx hsd industrial/appli msd gross margin declin y/i primarili driven unfavor mix dilut patheon dilut gross margin expens line forecast percentag sale basi sg expens forecast absolut basi percentag sale basi sg includ headwind relat one-tim bonu payment despit gross margin come weaker expect oper margin light consensu forecast abl gener leverag oper expens addit note oper margin neg impact relat one-tim bonu payment exclud payment contempl consensu prior guidanc oper margin expect cowen
compani report cowen compani
mm except yr cagrcommentstot y/i organ fx life scienc core growth slightli higher averag due time holiday difficult product growth growth currenc growth scienc growth like highest ai follow lss lp sdxreport growth growth net growth like highest ai follow lss lp sdxreport growth growth could driver higher growth yearsacquisit net growth like highest ai follow lss lp sdxreport growth growth net product servic growth like highest ai follow lss lp sdxreport growth growth note estim pthn accret lp growth assum base growth net trial logist busi margin impact custom cancel phase studyforeign annual cowen
compani report thomson eikon cowen compani
mm except per share cagrcommentsnet y/i organ fx core growth slightli higher averag due time holiday difficult comporgan gener oper y/i includ dilut margin y/i margin flatincrement margin significantli benefit bonu pthn pr easi comp pthn annual interest net interest payment interest rate increas everi expens immaterialearn add earn per fx phase gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
